MaxCyte (NASDAQ:MXCT) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement. Analysts anticipate MaxCyte to report an ...
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and ...
MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet ...
MaxCyte, Inc., a company specializing in cell engineering to facilitate the development of cell therapeutics, announced that it will release its financial results for the second quarter of 2025 on ...
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback